Under construction – not a live service
Sign in
Taking peoplePhase 4

Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis

Key facts

Phase
Phase 4

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Assiut University
Trial code
NCT06209047
Record updated
17 July 2025
Original description
Randomized single-center trial evaluating whether bronchoscopic instillation of levofloxacin or gentamicin improves outcomes compared to a sham bronchoscopic procedure in adult ICU patients with non-cystic fibrosis bronchiectasis requiring invasive mechanical ventilation. The primary outcome is a ranked composite of in-hospital mortality and time to ventilator liberation. Safety and procedural adverse events are closely monitored.Read full original descriptionShow less

A Randomized Sham-Controlled Trial of Bronchoscopic Levofloxacin and Gentamicin Versus Sham in Mechanically Ventilated Bronchiectasis: Acute and 1-Year Outcomes

Randomized single-center trial evaluating whether bronchoscopic instillation of levofloxacin or gentamicin improves outcomes compared to a sham bronchoscopic procedure in adult ICU patients with non-cystic fibrosis bronchiectasis requiring invasive mechanical ventilation. The primary outcome is a ranked composite of in-hospital mortality and time to ventilator liberation. Safety and procedural adverse events are closely monitored.

Inclusion: patients with bronchiectasis confirmed by high-resolution CT chest(HRCT); patients with acute exacerbation of bronchiectasis who need antibiotic treatment at the hospital due to exacerbation; mechanically ventilated patients in the respiratory ICU; Age more than or equal to 18 years.

Exclusion: patients with active pulmonary tuberculosis; patients with allergic bronchopulmonary aspergillosis; age less than 18 years; patients who underwent interventional bronchoscopy for hemoptysis.

ClinicalTrials.gov NCT06209047